ENDPOINTS

Eli Lilly inks deal with Camurus for its long-acting obesity tech

Eli Lilly has tapped Camurus in a deal worth up to $870 million for its drug delivery technology to develop four long-acting incretin candidates. The technology can be used on any of Lilly’s dual GIP ...

Jun 4, 2025 - 11:44
 0
Eli Lilly inks deal with Camurus for its long-acting obesity tech
Eli Lilly has tapped Camurus in a deal worth up to $870 million for its drug delivery technology to develop four long-acting incretin candidates. The technology can be used on any of Lilly’s dual GIP ...
Read More

Tags:

Previous Article

Most people obey arbitrary rules even when it's not in their interest to do so, ...

Next Article

This $65 Costco Gold Star Membership comes with a $20 Digital Costco Shop Card*

Related Posts

Investors pump $130M into protein degrader startup GlycoEra

Investors pump $130M into protein degrader startup Glyc...

May 27, 2025  0

#ASCO25: Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

#ASCO25: Gilead, Merck reveal 'practice-changing' data ...

May 31, 2025  0

Omada Health prices IPO at $19 a share, $1.1B valuation

Omada Health prices IPO at $19 a share, $1.1B valuation

Jun 6, 2025  0